2 Minute Medicine |
Mepolizumab reduces exacerbations in severe eosinophilic asthma [MENSA trial]
2 Minute Medicine 1. The rate of asthma exacerbations was significantly reduced in patients with severe eosphinophilic asthma receiving either intravenous or subcutaneous mepolizumab, compared to patients receiving placebo. 2. The safety profile of mepolizumab was … Seven developments in asthma research |
View full post on asthma – Google News